Literature DB >> 18513192

Magnetic resonance imaging accuracy in assessing tumour down-staging following chemoradiation in rectal cancer.

A Suppiah1, I A Hunter, J Cowley, V Garimella, J Cast, J E Hartley, J R T Monson.   

Abstract

OBJECTIVE: Magnetic resonance imaging (MRI) is increasingly accepted as the radiological modality of choice staging rectal cancer but is subject to error. Neoadjuvant therapy is increasingly used in rectal cancer and MRI is used to stage response and occasionally plan surgery. We aim to assess the staging accuracy of MRI following chemoradiotherapy in rectal cancer.
METHOD: Retrospective analysis of 86 patients with MRI stage pre- and postlong-course chemoradiotherapy and comparison with pathological assessment.
RESULTS: Fourty-nine patients (34 men, 15 women) with median age 68 years (60-74) were analysed. The median time from completion of CRT to MRI was 32 days (16-37). Chemoradiotherapy led to significant down-staging (P < 0.001). MRI-staging accuracy was 43% (21/49) with over- and under-staging in 43% (21/49) and 14% (7/49) respectively. T-stage accuracy was 45% (22/49) with over-staging in 33% (16/49) and under-staging in 22% (11/49). MRI stage correlated poorly with pathological assessment for International Union Against Cancer (kappa = 0.255) and T stages (kappa = 0.112). MRI nodal assessment was 71% (35/49) accurate, with 82% (9/11) sensitivity, 68% (26/38) specificity and positive predictive value (PPV) of 43% (9/21) and negative predictive value of 93% (26/28). There was a significant difference in node positivity between MRI and pathological staging (P = 0.005, Fisher's exact). Complete radiological response was observed in 4% (2/49). Complete pathological response was observed in 10% (5/49), which were staged 0(1), I(1), II(2) and III(1) postchemoradiotherapy by MRI.
CONCLUSION: MRI staging following chemoradiation is poor. Over-staging occurs three times more commonly than under-staging. Over-staging is due to poor PPV of nodal assessment.

Entities:  

Mesh:

Year:  2008        PMID: 18513192     DOI: 10.1111/j.1463-1318.2008.01593.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  27 in total

1.  Neoadjuvant chemoradiotherapy of the rectal carcinoma - The correlation between the findings on the restaging multiparametric 3T MRI scanning and the surgical findings.

Authors:  Radovan Vojtíšek; Eva Korčáková; Jan Mařan; Ondřej Šorejs; Jindřich Fínek
Journal:  Rep Pract Oncol Radiother       Date:  2017-05-05

2.  Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer.

Authors:  Davide Ippolito; Davide Fior; Chiara Trattenero; Elena De Ponti; Silvia Drago; Luca Guerra; Cammillo Talei Franzesi; Sandro Sironi
Journal:  World J Radiol       Date:  2015-12-28

3.  The impact of lymph node size to predict nodal metastasis in patients with rectal cancer after preoperative chemoradiotherapy.

Authors:  Im-Kyung Kim; Jeonghyun Kang; Beom Jin Lim; Seung-Kook Sohn; Kang Young Lee
Journal:  Int J Colorectal Dis       Date:  2015-01-15       Impact factor: 2.571

4.  MR imaging of rectal cancer before and after chemoradiation therapy.

Authors:  R Del Vescovo; L E Trodella; I Sansoni; R L Cazzato; S Battisti; F Giurazza; S Ramella; F Cellini; R F Grasso; L Trodella; B Beomonte Zobel
Journal:  Radiol Med       Date:  2012-03-20       Impact factor: 3.469

Review 5.  Magnetic resonance imaging in rectal cancer: a surgeon's perspective.

Authors:  Avanish P Saklani; Sung Uk Bae; Amy Clayton; Nam Kyu Kim
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

6.  Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study.

Authors:  Luca Sorrentino; Marcello Guaglio; Luigi Battaglia; Giuliano Bonfanti; Marco Vitellaro; Alessandro Cesa Bianchi; Massimo Milione; Filiberto Belli
Journal:  Int J Colorectal Dis       Date:  2019-11-18       Impact factor: 2.571

7.  Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Authors:  M J Gollub; D H Gultekin; O Akin; R K Do; J L Fuqua; M Gonen; D Kuk; M Weiser; L Saltz; D Schrag; K Goodman; P Paty; J Guillem; G M Nash; L Temple; J Shia; L H Schwartz
Journal:  Eur Radiol       Date:  2011-11-20       Impact factor: 5.315

Review 8.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

9.  Prediction of tumor stage and lymph node involvement with dynamic contrast-enhanced MRI after chemoradiotherapy for locally advanced rectal cancer.

Authors:  Wijnand J Alberda; Helene P N Dassen; Roy S Dwarkasing; François E J A Willemssen; Anne E M van der Pool; Johannes H W de Wilt; Jacobus W A Burger; Cornelis Verhoef
Journal:  Int J Colorectal Dis       Date:  2012-09-22       Impact factor: 2.571

10.  Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.

Authors:  Ji-In Bang; Seunggyun Ha; Sung-Bum Kang; Keun-Wook Lee; Hye-Seung Lee; Jae-Sung Kim; Heung-Kwon Oh; Ho-Young Lee; Sang Eun Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.